TECHNICAL NOTE

Quantification of eight antimycotics in human plasma by liquid chromatography-tandem mass spectrometry for clinical research

Authors: Gaëtan Renoulin¹, Claudio De Nardi² ¹Thermo Fisher Scientific, Les Ulis, France ²Thermo Fisher Scientific, Reinach, Switzerland

Keywords: TraceFinder software, TSQ Quantis MS, Vanquish Flex UHPLC, antifungals, antimycotics, offline sample preparation, plasma

Application benefits

- Robust, sensitive hardware enables increased confidence in data
- Simple offline sample preparation by protein precipitation
- Eight antimycotics drugs in a single 3.6-minute quantitative method

Goal

Implementation of an analytical method for the quantification of eight antimycotics in human plasma on a Thermo Scientific[™] TSQ Quantis[™] triple quadrupole mass spectrometer.



Introduction

Antifungals, also known as antimycotics, typically refer to a class of pharmaceutical fungicide used to treat and prevent mycosis, ranging from athlete's foot to ringworm to serious infections, such as cryptococcal meningitis. Voriconazole, posaconazole, fluconazole, ketoconazole, and other similar antimycotics are used to treat lifethreatening fungal infections along with prevention of infections in immunocompromised individuals. The narrow



therapeutic ranges of these antifungal agents, in addition to other complications, could lead to very different drug exposure from even the same dosage regimen and, therefore, very different individual outcomes. Analytical methods to quantify such antimycotics were traditionally performed using high-performance liquid chromatography (HPLC) coupled with UV detectors. However, these methods require complicated extraction procedures and time-consuming chromatography. LC-MS based methods are known for their superior selectivity and often result in significant reduction of the time spent on complicated sample preparation procedures and chromatography.

An analytical method for clinical research to quantify eight antimycotics in human plasma in 3.6 minutes is presented in this report. Samples were prepared by protein precipitation followed by chromatographic separation on a Thermo Scientific[™] Vanquish[™] Flex Binary UHPLC system. Detection was performed on a TSQ Quantis triple quadrupole mass spectrometer with heated electrospray ionization (HESI) operated in positive ionization mode. Method performance was evaluated using the ClinMass[®] TDM Platform with the ClinMass Add-On Set for Antimycotics by RECIPE Chemicals + Instruments GmbH (Munich, Germany) in terms of linearity of response, lower limit of quantification (LLOQ), carryover, accuracy, and intra- and inter-assay precision for all analytes.

Experimental

Target analytes

The complete list of analytes with their corresponding internal standards and the concentration ranges covered by the calibrators used are reported in Table 1. They include 5-fluorocytosine, fluconazole, isavuconazole, itraconazole, ketoconazole, OH-itraconazole, posaconazole, and voriconazole.

Sample preparation

Reagents included four calibrators (including blank) and two controls from RECIPE, as well as an internal standard mix for quantitation. Samples of 50 μ L of plasma-based calibrators and controls were protein precipitated using 100 μ L of acetonitrile containing the internal standards. Precipitated samples were vortex-mixed and centrifuged for 10 minutes. Fifty microliters of the supernatant were transferred to a clean vial and diluted to a volume of 500 μ L with water.

Liquid chromatography

The diluted supernatant was injected onto a Vanquish Flex Binary UHPLC system connected to a TSQ Quantis triple quadrupole mass spectrometer. Chromatographic separation was achieved by gradient elution on a Thermo Scientific[™] Hypersil GOLD[™] 50 × 2.1 mm (1.9 µm) column kept at 40 °C.

Mobile phases composition was the following:

- Mobile phase A: Water + 0.1 % formic acid
- Mobile phase B: Acetonitrile + 0.1 % formic acid

Injection volume was 2 $\mu\text{L}.$ MeOH/water (50/50) was used as needle wash solvent.

The LC gradient is described in detail in Table 2. Total runtime was 3.6 minutes.

Table 2. LC gradient profile

Time (min)	Flow (mL/min)	%В
0.0	0.5	5
0.5	0.5	5
1.5	0.5	100
2.5	0.5	100
2.6	0.5	5
3.6	0.5	5

Table 1. Analytes, concentrations ranges (MS9613, batch #1369), and internal standards

Compound name	Molecular formula	Concentration range (mg/L)	Internal standard name	Molecular formula
5-Fluorocytosine	$C_4H_4FN_3O$	4.90–108	¹³ C- ¹⁵ N ₂ -5-Fluorocytosine	$^{13}C^{15}N_2C_3H_4FNO$
Fluconazole	C ₁₃ H ₁₂ F ₂ N ₆ O	0.622–13.5	d ₄ -Fluconazole	$C_{13}H_8D_4F_2N_6O$
Isavuconazole	C ₂₂ H ₁₇ F ₂ N ₅ OS	0.481–10.8	¹³ C-d ₄ -Isavuconazole	¹³ CC ₂₁ H ₁₃ D ₄ F ₂ N ₅ OS
Itraconazole	$C_{35}H_{38}CI_2N_8O_4$	0.146–3.11	d ₅ -Itraconazole	$C_{35}H_{33}D_5Cl_2N_8O_4$
Ketoconazole	$C_{26}H_{28}CI_2N_4O_4$	0.430-8.88	d ₈ -Ketoconazole	$C_{26}H_{20}D_8Cl_2N_4O_4$
OH-Itraconazole	$C_{35}H_{38}CI_2N_8O_5$	0.171-3.55	d5-OH-Itraconazole	$C_{35}H_{33}D_5Cl_2N_8O_5$
Posaconazole	$C_{37}H_{42}F_2N_8O_4$	0.233-4.90	d ₄ -Posaconazole	C ₃₇ H ₃₈ D ₄ F ₂ N ₈ O ₄
Voriconazole	$C_{16}H_{14}F_{3}N_{5}O$	0.275-5.96	d ₃ -Voriconazole	$C_{16}H_{11}D_{3}F_{3}N_{5}O$

Mass spectrometry

Analytes and internal standard were detected by Selected Reaction Monitoring (SRM) on a TSQ Quantis triple quadrupole mass spectrometer using a HESI source operated in positive ionization mode. A summary of the MS conditions is reported in Table 3. One confirming ion for each analyte was included in the acquisition method for confirmation (Table 4).

Table 3. MS parameters

lon source parameters							
Source type	Heated Electrospray Source Ionization (HESI)						
Spray voltage - Positive (V)	3,750						
Sheath gas (Arb)	55						
Aux gas (Arb)	10						
Sweep gas (Arb)	2						
lon transfer tube temp. (°C)	320						
Vaporizer temp. (°C)	450						
Settings							
Data acquisition mode	SRM						
SRM parameters							
Cycle time (s)	0.3						
Q1 resolution (FWHM)	0.7						
Q3 resolution (FWHM)	1.2						
Chromatographic peak width(s)	6						

Method evaluation

The performance of the method was evaluated in terms of linearity of response, LLOQ, carryover, accuracy, and intraand inter-assay precision for all analytes.

A 20-fold serial dilution of the lowest calibrator using blank matrix was performed to evaluate the LLOQ. A full set of calibrators (four levels) and diluted calibrators (two levels) were injected in a single batch and all used for the linear interpolation. The LLOQ was set as the lowest level that could be determined with a CV < 20%.

Carryover was calculated in terms of percentage ratio between peak area of the highest calibrator and a subsequent blank sample injection. Analytical accuracy was evaluated in terms of percentage bias between nominal and average calculated concentrations using quality control samples at two different levels provided by RECIPE (MS9682 batch #1369).

Quality control samples were prepared and analyzed in replicates of five over three different days. Intraassay precision for each day was evaluated in terms of percentage coefficient of variation (%CV) using the controls at two different levels in replicates of five (n=5). Inter-assay precision was evaluated as the %CV on the full set of samples (control samples at two levels in replicates of five prepared and analyzed on three different days, n=15).

		Quantification						
Analyte / internal standard	Retention (min)	Precursor ion (<i>m/z</i>)	Product ion (<i>m/z</i>)	Collision energy (V)	Precursor ion (<i>m/z</i>)	Product ion (<i>m/z</i>)	Collision energy (V)	RF lens (V)
5-Fluorocytosine	0.3	130.1	58.0	32	130.1	113.0	19	78
Fluconazole	1.4	306.9	238.1	15	306.9	220.0	17	110
Isavuconazole	1.8	438.1	224.0	20	438.1	369.0	18	138
Itraconazole	1.8	705.2	392.2	35	705.2	404.2	33	140
Ketoconazole	1.6	531.1	489.1	30	531.1	244.0	33	120
OH-Itraconazole	1.7	721.2	408.2	35	721.2	392.2	34	140
Posaconazole	1.7	701.3	614.3	34	701.3	344.1	43	200
Voriconazole	1.7	350.0	281.0	15	350.0	127.0	33	111
$^{13}\text{C-}^{15}\text{N}_2\text{-}5\text{-}Fluorocytosine}$	0.3	133.1	115.0	32	133.1	/	/	78
d ₄ -Fluconazole	1.4	310.9	242.1	22	310.9	/	/	110
¹³ C-d ₄ -Isavuconazole	1.8	443.1	224.0	18	443.1	/	/	138
d ₅ -Itraconazole	1.8	710.2	397.2	35	710.2	/	/	140
d ₈ -Ketoconazole	1.6	539.1	497.1	33	539.1	/	/	120
d ₅ -OH-Itraconazole	1.7	726.2	413.2	34	726.2	/	/	140
d ₄ -Posaconazole	1.7	705.3	618.3	43	705.3	/	/	200
d ₃ -Voriconazole	1.7	353.0	353.0	33	353.0	/	/	111

Table 4. Description of the SRM parameters

Data analysis

Data were acquired and processed using Thermo Scientific[™] TraceFinder[™] 5.1 software.

Results and discussion

A linear interpolation with 1/x weighting was used for all analytes. The percentage bias between nominal and back-calculated concentration was always within ±6.0% for all the calibrators in all the runs. Representative chromatograms at the LLOQ for 5-fluorocytosine, isavuconazole, ketoconazole, voriconazole, and their corresponding internal standards are reported in Figure 1. Representative calibration curves for the same analytes are reported in Figure 2. No carryover was observed for any of the analytes, with no signal detected in the blank injected immediately after the highest calibrator.

The data demonstrated good accuracy of the method with the percentage bias between nominal and average back-calculated concentration for control samples ranging between -5.5% and 5.1% (Table 5). The %CV for intraassay precision was always below 12.4% for all analytes. The maximum %CV for inter-assay precision including all analytes was 10.8%. Results for intra- and inter-assay precision are reported in Table 6.

LLOQs of all compounds are reported in Table 7.



Figure 1. Representative chromatograms of the lower limit of quantification for (a) 5-fluorocytosine, (b) isavuconazole, (c) ketoconazole, (d) voriconazole, (e) ${}^{13}C_{-}{}^{15}N_{2}$ -5-fluorocytosine, (f) ${}^{13}C_{-}d_{4}$ - isavuconazole, (g) d_a-ketoconazole, (h) d_a-voriconazole



Figure 2. Representative calibration curves for (a) 5-fluorocytosine, (b) isavuconazole, (c) ketoconazole, (d) voriconazole

Analyte	Control	Nominal concentration (mg/L)	Average calculated concentration (mg/L)	Bias (%)
5 Elucropytopipo	Level I	19.9	19.1	-4.0
5-1 luorocytosine	Level II	46.7	48.1	3.1
Elucopazolo	Level I	2.43	2.42	-0.5
FIUCONAZOIE	Level II	5.79	6.00	3.6
	Level I	1.95	1.98	1.7
ISavuconazoie	Level II	4.59	4.82	5.1
ltrooppozolo	Level I	0.590	0.562	-4.8
Itraconazoie	Level II	1.31	1.38	5.1
Kataopazala	Level I	1.71	1.62	-5.5
Reloconazoie	Level II	3.90	4.02	3.2
OH Itracopazala	Level I	0.678	0.665	-2.0
OH-Itraconazoie	Level II	1.60	1.57	-1.7
Posaconazole	Level I	0.909	0.883	-2.8
	Level II	2.19	2.17	-1.0
Voricopazolo	Level I	1.10	1.14	3.4
VUIIGUIIAZUIE	Level II	2.59	2.69	4.0

Table 5. Analytical accuracy results for control MS9682 batch #1369

thermo scientific

Table 6. Analytical intra- and inter-assay precision results for control MS9682 batch #1369

			Inter-assay						
		Day 1		Day 2		Day 3			
Compound name	Control	Average calculated concentration (mg/L)	CV (%)	Average calculated concentration (mg/L)	CV (%)	Average calculated concentration (mg/L)	CV (%)	Average calculated concentration (mg/L)	СV (%)
C. Elvere entreire e	Level I	19.3	1.5	19.0	4.2	19.0	2.7	19.1	1.1
5-Fluorocytosine	Level II	48.0	10.6	49.6	4.7	46.8	4.3	48.1	2.9
Fluconazole	Levell	2.39	1.6	2.42	3.10	2.43	2.5	2.42	0.9
	Level II	5.92	11.5	6.28	2.9	5.79	2.9	6.00	4.3
Isavuconazole	Level I	2.06	3.2	1.93	3.8	1.96	3.5	1.98	3.5
	Level II	4.81	12.4	5.00	2.4	4.65	4.1	4.82	3.7
Itraconazole	Level I	0.603	2.7	0.545	2.8	0.538	3.2	0.562	6.3
	Level II	1.41	11.9	1.46	3.4	1.26	6.0	1.38	7.3
Kalananala	Level I	1.67	7.7	1.57	3.5	1.61	1.5	1.62	2.9
Ketoconazole	Level II	4.09	11.3	4.16	3.5	3.82	4.5	4.02	4.5
OH-Itraconazole	Level I	0.716	5.3	0.657	6.2	0.622	4.9	0.665	7.2
	Level II	1.58	7.9	1.66	6.8	1.48	5.4	1.57	5.6
Posaconazole	Level I	0.97	10.0	0.844	10.8	0.840	7.0	0.883	8.2
	Level II	2.25	7.8	2.35	11.3	1.90	8.5	2.17	10.8
	Levell	1.10	6.1	1.07	4.7	1.04	6.9	1.07	2.4
voriconazoie	Level II	2.61	10.1	2.64	5.1	2.62	4.1	2.62	0.5

Table 7. LLOQs for all compounds

Analyte	LLOQ (mg/L)
5-Fluorocytosine	0.245
Fluconazole	0.0622
Isavuconazole	0.0481
Itraconazole	0.0292
Ketoconazole	0.0430
OH-Itraconazole	0.0342
Posaconazole	0.233
Voriconazole	0.0138

Conclusions

A robust, reproducible, and sensitive liquid chromatography-tandem mass spectrometry method for clinical research for quantification of eight antimycotics in human plasma was developed and implemented. The analytical method was validated on an Vanquish Flex Binary UHPLC system coupled to a TSQ Quantis triple quadrupole mass spectrometer. The method described here offers quick and simple offline protein precipitation with concomitant internal standard addition using the ClinMass TDM Platform with the ClinMass Add-On Set for Antimycotics from RECIPE. The described method meets research laboratory requirements in terms of sensitivity, linearity of response, accuracy, and precision.

Find out more at thermofisher.com/ClinicalResearchApps

For General Lab Use only. Not for use in diagnostic procedures. © 2021 Thermo Fisher Scientific Inc. All rights reserved. ClinMass is a registered trademark of RECIPE Chemicals + Instruments GmbH. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries. This information is presented as an example of the capabilities of Thermo Fisher Scientific Inc. products. It is not intended to encourage use of these products in any manners that might infringe the intellectual property rights of others. Specifications, terms and pricing are subject to change. Not all products are available in all countries. Please consult your local sales representative for details. TN66059-EN 0721S

